Australia's most trusted
source of pharma news
Posted 18 December 2023 AM
The PBAC considered 18 change to listing requests at its November meeting, with some big names getting the nod.
Sanofi scored a win, with PBAC recommending immunotherapy Libtayo as a first line treatment in combination with platinum doublet chemotherapy for people with stage IV non-small cell lung cancer with no evidence of epidermal growth factor receptor, anaplastic lymphoma kinase, or c-ROS-proto-oncogene 1 aberrations. This joins another recommendation for NSCLC given a year ago, but not acted upon.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.